We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+15.6%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$707M
AUM Growth
+$45.6M
Cap. Flow
-$35.7M
Cap. Flow %
-5.06%
Top 10 Hldgs %
81.61%
Holding
26
New
4
Increased
7
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$46.7M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$42.9M
3
PEN icon
Penumbra
PEN
+$34.7M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$27.5M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$24.5M

Top Sells

Rank Stock Value
1
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$49.2M
2
ABBV icon
AbbVie
ABBV
+$47.6M
3
NUVA
NuVasive, Inc.
NUVA
+$45.4M
4
PACB icon
Pacific Biosciences
PACB
+$31.1M
5
AGN
Allergan plc
AGN
+$25.5M

Sector Composition

Rank Sector Weight
1 Healthcare 88.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNK
1
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$94.8M 13.42%
1,560,157
+450,157
+41% +$27.5M
MDVN
2
DELISTED
MEDIVATION, INC.
MDVN
$76.6M 10.84%
1,270,000
-80,000
-6% -$4.54M
ARIA
3
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$65.4M 9.25%
8,845,742
+3,270,000
+59% +$24.5M
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$614M
$64.4M 9.12%
5,885,392
-17,910
-0.3% -$175K
OFIX icon
5
Orthofix Medical
OFIX
$477M
$51.9M 7.35%
1,224,496
-281,400
-19% -$12.2M
TVTX icon
6
Travere Therapeutics
TVTX
$5.33B
$48.1M 6.81%
2,699,947
-30,000
-1% -$486K
ANIP icon
7
ANI Pharmaceuticals
ANIP
$1.83B
$45.6M 6.46%
817,456
-210,908
-21% -$10.3M
ASRT
8
DELISTED
Assertio
ASRT
$44.6M 6.32%
37,922
-8,017
-17% -$8.76M
UTHR icon
9
United Therapeutics
UTHR
$26.2B
$44.3M 6.28%
+418,700
New +$46.7M
PEN icon
10
Penumbra
PEN
$12.6B
$40.7M 5.76%
684,079
+644,079
+1,610% +$34.7M
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
$40.3M 5.7%
+2,936,487
New +$42.9M
EGRX
12
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$18.7M 2.65%
482,047
-211,890
-31% -$8.82M
NXTM
13
DELISTED
NxStage Medical Inc.
NXTM
$18.1M 2.56%
+835,134
New +$14.9M
CPHD
14
DELISTED
Cepheid Inc
CPHD
$13.9M 1.97%
+453,662
New +$13.7M
NUVA
15
DELISTED
NuVasive, Inc.
NUVA
$9.87M 1.4%
165,203
-839,797
-84% -$45.4M
PACB icon
16
Pacific Biosciences
PACB
$460M
$7.84M 1.11%
1,114,448
-3,403,069
-75% -$31.1M
ADMA icon
17
ADMA Biologics
ADMA
$2.01B
$7.58M 1.07%
1,273,933
+213,916
+20% +$1.5M
VCEL icon
18
Vericel Corp
VCEL
$2.43B
$5.02M 0.71%
2,232,940
– –
AXGN icon
19
Axogen
AXGN
$2.2B
$3.62M 0.51%
526,351
+120,000
+30% +$679K
SPNE
20
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$2.68M 0.38%
255,334
+88,036
+53% +$1.06M
BIOL
21
DELISTED
Biolase, Inc.
BIOL
$1.47M 0.21%
101
+1
+1% +$15.8K
VCYT icon
22
Veracyte
VCYT
$4.77B
$834K 0.12%
165,825
– –
ABBV icon
23
AbbVie
ABBV
$455B
– –
-833,000
Closed -$47.6M
AGN
24
DELISTED
Allergan plc
AGN
– –
-95,000
Closed -$25.5M
MACK
25
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-746,734
Closed -$49.2M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Consonance Capital Management held 26 positions worth $707M, up 6.9% from $661M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Consonance Capital Management withdrew a net $35.7M in Q2 2016, closing 4 positions and reducing 9 holdings. Its most notable exit was Merrimack Pharmaceuticals, Inc., an estimated $49.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in United Therapeutics worth $44.3M.

  • Consonance Capital Management's largest Q2 2016 buy was United Therapeutics: 418,700 shares worth $44.3M.
  • Consonance Capital Management added most to Penumbra in Q2 2016, an estimated $34.7M increase.
  • Consonance Capital Management's biggest Q2 2016 reduction was NuVasive, Inc., cutting an estimated $45.4M.
  • Consonance Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2016, selling an estimated $49.2M.
  • Consonance Capital Management's ten largest holdings make up 82% of its $707M portfolio in Q2 2016.
  • Consonance Capital Management opened 4 new positions and closed 4 in Q2 2016.
  • Consonance Capital Management's portfolio value rose 6.9% quarter-over-quarter to $707M.

Based on Consonance Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.